Bonjour et al., 1983 - Google Patents
68 Pathophysiology of hypercalcemia of malignancyBonjour et al., 1983
- Document ID
- 852990668824560576
- Author
- Bonjour J
- Jung A
- Rizzoli R
- Publication year
- Publication venue
- Journal of Steroid Biochemistry
External Links
- 206010020584 Hypercalcaemia of malignancy 0 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P-C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jowsey et al. | The treatment of osteoporosis with disodium ethane-1-hydroxy-1, 1-diphosphonate | |
| Mundy et al. | Comparative study of available medical therapy for hypercalcemia of malignancy | |
| Warrell et al. | Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. | |
| Bonjour et al. | Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate | |
| Harris et al. | The mode of action of vitamin D: Studies on hypervitaminosis D. The influence of the calcium-phosphate intake | |
| US3683080A (en) | Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue | |
| Russell et al. | Treatment of myositis ossificans progressiva with a diphosphonate | |
| Stover et al. | Disodium etidronate in the prevention of postoperative recurrence of heterotopic ossification in spinal-cord injury patients | |
| Reifenstein Jr et al. | Paget's disease: its pathologic physiology and the importance of this in the complications arising from fracture and immobilization | |
| Paterson et al. | The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma | |
| JPH06505501A (en) | How to treat osteoporosis | |
| US4086334A (en) | Composition and method for the treatment of disorders of calcium metabolism | |
| Galante et al. | Bilateral adrenalectomy for advanced carcinoma of the breast with preliminary observations on the effect of the liver on the metabolism of adrenal cortical steroids | |
| Wüster et al. | Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia | |
| Jung et al. | Parenteral diphosphonates for treating malignant hypercalcemia | |
| EP0497845A1 (en) | Bafilomycine macrolides for treatment of bone affecting diseases | |
| Bonjour et al. | 68 Pathophysiology of hypercalcemia of malignancy | |
| Wiegele et al. | 67 Aminoglutethimide in postmenopausal women with metastatic breast cancer who no longer responded to other hormonal or cytotoxic treatment | |
| Valentin-Opran et al. | 69 Hypercalcemia of malignancy: Pathogenesis and treatment | |
| JPS58208232A (en) | Antiinflammatory and antirheumatic composition containing organophosphate and steroid | |
| Tong | Parathormone and 32P therapy in prostatic cancer with bone metastases | |
| AU2010232694B2 (en) | Method of treating osteoporosis | |
| Bundred et al. | Parathyroid hormone-related protein, bone metastases and hypercalcaemia of malignancy. | |
| Reich | Advances in the treatment of bone metastases | |
| Stock et al. | Medical management of primary hyperparathyroidism |